Press release
CARDIOREG Alliance: ZeClinics and Taros to Develop New Heart Regeneration Therapies
CARDIOREG Alliance: ZeClinics and Taros to Develop New Heart Regeneration Therapies
"We are thrilled that Taros has joined our efforts to identify therapeutic targets promoting heart regeneration after ischemic injury. Their extensive knowledge in drug discovery including computer-aided drug design will prove pivotal in identifying hit and lead compounds," said Dr. Simone Calzolari, chief commercial officer at ZeClinics.
Taros will be responsible for hit generation and optimization, involving in silico screening as well as synthesis of the hit candidate. ZeClinics in turn will evaluate the pro-regenerative function of candidate genes through the development of zebrafish transgenic models and the in vivo characterization of relevant cardiovascular parameters with their ZeCardio software platform.
"Cardiac regeneration can effectively compensate the loss of cardiac muscle after ischemic injury but molecular mechanisms enabling it are dormant in humans," said Dr. Torsten Hoffmann, Senior Vice President Drug Discovery at Taros. "We have an exciting opportunity to discover new molecules promoting heart functional recovery upon ischemia."
CARDIOREG falls under the German-Catalonian Joint Research and Development Project. The project will be overseen by the German BMWi, the Catalan ACCIÓ and AiF Projekt GmbH.
About Zeclinics SL
ZeClinics is an innovative biotech firm committed to streamlining discovery and preclinical development of novel compounds with zebrafish, an ideal vertebrate model for fast, cost-effective and highly predictive assessments. ZeClinics combines in-house academic expertise with a diversified, cutting-edge portfolio: from CRISPR-licensed gene editing, high-throughput safety and efficacy assays to disease models. For more information: www.zeclinics.com
About Taros Chemicals
Taros, a privately owned CRO has been serving pharmaceutical, biotech and chemical companies since 1999. Within our drug discovery division, our mission is to accelerate potential new medicines into clinical development. Taros adds considerable value to drug discovery collaborations by boosting collaborators' discovery programs from target validation and hit identification to lead generation and optimization. Taros' capabilities include medicinal chemistry, computational sciences and innovative compound libraries. Taros has been leading the chemistry activities of the European Lead Factory (ELF), EU's 196 million EUR drug discovery platform and is involved in the 11 million EUR Drug Discovery Hub Dortmund. For more information: www.taros.de
Contact:
Taros Chemicals GmbH & Co. KG
Youri R. Mesmoudi
Emil-Figge-Str. 76a
44269 Dortmund
Tel.: +49(0)231-974272-11
e-mail: info@taros.de
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release CARDIOREG Alliance: ZeClinics and Taros to Develop New Heart Regeneration Therapies here
News-ID: 1547220 • Views: …
More Releases from Taros Chemicals GmbH & Co. KG
Partnership: Ehrfeld and Taros Collaborate to Promote Early Adoption of Flow Che …
+++ 15.05.2024 Germany +++ Ehrfeld Mikrotechnik, a leading provider of reactors, mixers, and heat exchangers for micro reaction technology located in Wendelsheim, and Taros, with HQ in Dortmund, a globally active custom research and manufacturing organization serving the chemical, pharmaceutical and biotech industries, are jointly paving the way for a smooth access and deployment of flow chemistry as a high-performance and forward-looking research and production tool in chemical synthesis processes.…
Taros Chemicals’ SVP Dr. Torsten Hoffmann appointed as chairman to EV-TT’s S …
A research cooperation of the Paracelsus Medical University Salzburg and the Paris Lodron University Salzburg co-founded a „Transfer Center for Extracellular Vesicles – Theralytic Technologies“ (EV-TT) to conduct fundamental and applied biomedical research and development with a focus on revolutionary and innovative, regenerative medicine and drug delivery approaches using extracellular vesicles. The project has a total volume of € 3.6 million and received funding from Land Salzburg/IWB/EFRE 2014-2020 and Land…
The European Lead Factory, Europe’s largest collaborative drug discovery platf …
Seeding tomorrow’s priority medicines – Taros Chemicals to renew its participation
The European Lead Factory (ELF) secured a total project budget of EUR 36.5 million under the second framework of the Innovative Medicines Initiative (IMI). Over the next 5 years, 20 partners in 7 countries will push forward the transformation of potential drug targets to new medicines in the new project ESCulab (European Screening Centre: unique library for attractive biology) under…
Taros Chemicals Appoints Torsten Hoffmann as Senior Vice President Drug Discover …
Taros Chemicals GmbH & Co. KG today announced the appointment of Dr Torsten Hoffmann as Senior Vice President Drug Discovery, effective October 1st, 2018. In his role, Torsten will further strengthen and accelerate Taros’ continued growth of its drug discovery business.
With more than 20 years of international R&D leadership experience, Torsten is an expert in the field of Drug Discovery. For the past 5 years he has served as Chief…
More Releases for ZeClinics
Zebrafish as a Model Organism Market Trends Analysis And Research Report to 2030 …
The latest report on the Zebrafish as a Model Organism Market provides a comprehensive overview of the industry's important characteristics, including production, market growth rate, industry share, consumption value and volume, demand for specific types of products and services, and more. The publication focuses on providing a competitive advantage to industry newcomers and those who aim to enter the market in the next years. It offers information on the most…
